Clinical Trial Update: Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ramelteon sublingual as adjunctive maintenance therapy for Bipolar I Disorder was terminated, and efficacy and safety results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ramelteon Sublingual (ramelteon)

Snippet

Sponsor: Takeda | Conditions: Bipolar Disorder | Phase 3 | Status: TERMINATED | Results posted: 2016-05-16